Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. “Completing this work in the midst of…
Latest News
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO
West High Yield Resources (WHY.V) announces milestone for Magnesium Project
Top 5 Gainers and Losers: GXU.V, SANU.CN, BTR.V
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request